STOCK TITAN

[8-K] Virios Therapeutics, Inc. Common Stock Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

Dillard’s, Inc. (DDS) Form 4 filing dated 07/02/2025 discloses a modest open-market purchase by long-time insider Drue Matheny, Executive Vice President and Director. On 06/30/2025 Matheny acquired 19 Class A common shares at $413.32 each, increasing her direct holding to 403,904 shares. She also continues to hold 36,648 shares through the company retirement plan and 9,821 shares indirectly (7,300 as trustee of the GST Trust and 2,521 held by her spouse). No derivative transactions were reported.

The purchase represents less than 0.005% of her direct ownership and is immaterial to DDS’s 17 million share float, yet any insider buying—particularly by a senior executive—may be interpreted as a confidence signal. There were no sales, option exercises, or 10b5-1 plan indications, and the filing confirms her continuing status as both officer and director.

Dillard’s, Inc. (DDS) ha presentato il modulo Form 4 in data 02/07/2025, rivelando un modesto acquisto sul mercato aperto da parte dell'insider di lunga data Drue Matheny, Vicepresidente Esecutivo e Direttore. Il 30/06/2025 Matheny ha acquisito 19 azioni ordinarie di Classe A al prezzo di $413,32 ciascuna, portando la sua partecipazione diretta a 403.904 azioni. Continua inoltre a detenere 36.648 azioni tramite il piano pensionistico aziendale e 9.821 azioni indirettamente (7.300 come fiduciario del GST Trust e 2.521 detenute dal coniuge). Non sono state segnalate transazioni su strumenti derivati.

L'acquisto rappresenta meno dello 0,005% della sua proprietà diretta ed è irrilevante rispetto alle 17 milioni di azioni in circolazione di DDS, tuttavia qualsiasi acquisto da parte di un insider—soprattutto da un dirigente senior—può essere interpretato come un segnale di fiducia. Non sono state effettuate vendite, esercizi di opzioni o indicazioni di piani 10b5-1, e il documento conferma il suo status continuativo sia come dirigente che come direttore.

Dillard’s, Inc. (DDS) presentó el formulario Form 4 con fecha 02/07/2025, revelando una modesta compra en el mercado abierto por parte de la veterana insider Drue Matheny, Vicepresidenta Ejecutiva y Directora. El 30/06/2025 Matheny adquirió 19 acciones ordinarias Clase A a $413.32 cada una, aumentando su participación directa a 403,904 acciones. También mantiene 36,648 acciones a través del plan de jubilación de la empresa y 9,821 acciones indirectamente (7,300 como fideicomisaria del GST Trust y 2,521 en posesión de su cónyuge). No se reportaron transacciones de derivados.

La compra representa menos del 0.005% de su propiedad directa y es insignificante en comparación con las 17 millones de acciones en circulación de DDS, sin embargo, cualquier compra por parte de un insider—especialmente un ejecutivo senior—puede interpretarse como una señal de confianza. No hubo ventas, ejercicios de opciones ni indicios de planes 10b5-1, y el informe confirma su estatus continuo como oficial y directora.

Dillard’s, Inc. (DDS)는 2025년 7월 2일자 Form 4 제출서에서 오랜 내부자이자 부사장 겸 이사인 Drue Matheny의 소규모 공개 시장 매수를 공개했습니다. 2025년 6월 30일 Matheny는 주당 $413.32에 클래스 A 보통주 19주를 매수하여 직접 보유 주식을 403,904주로 늘렸습니다. 또한 회사 퇴직연금 계획을 통해 36,648주를 보유하고 있으며, 간접적으로 9,821주 (GST 신탁의 수탁자로서 7,300주, 배우자가 보유한 2,521주)를 보유 중입니다. 파생상품 거래는 보고되지 않았습니다.

이번 매수는 그녀의 직접 소유 지분의 0.005% 미만으로 DDS의 1,700만 주 유통 주식에 비해 미미하지만, 특히 고위 임원의 내부자 매수는 신뢰 신호로 해석될 수 있습니다. 매도, 옵션 행사, 10b5-1 계획 관련 사항은 없었으며, 제출서류는 그녀가 계속해서 임원 및 이사임을 확인합니다.

Dillard’s, Inc. (DDS) a déposé le formulaire Form 4 daté du 02/07/2025, révélant un achat modeste sur le marché libre par Drue Matheny, une initiée de longue date, Vice-Présidente Exécutive et Directrice. Le 30/06/2025, Matheny a acquis 19 actions ordinaires de Classe A à 413,32 $ chacune, portant sa détention directe à 403 904 actions. Elle détient également 36 648 actions via le plan de retraite de l'entreprise et 9 821 actions indirectement (7 300 en tant que fiduciaire du GST Trust et 2 521 détenues par son conjoint). Aucune transaction sur dérivés n'a été rapportée.

L'achat représente moins de 0,005 % de sa propriété directe et est insignifiant par rapport aux 17 millions d'actions en circulation de DDS, mais tout achat par un initié—particulièrement un cadre supérieur—peut être interprété comme un signe de confiance. Il n'y a eu aucune vente, exercice d'options ou indication de plan 10b5-1, et le dépôt confirme son statut continu en tant que dirigeante et directrice.

Dillard’s, Inc. (DDS) hat am 02.07.2025 eine Form 4-Einreichung vorgenommen, die einen moderaten Kauf am offenen Markt durch die langjährige Insiderin Drue Matheny, Executive Vice President und Direktorin, offenlegt. Am 30.06.2025 erwarb Matheny 19 Class A Stammaktien zu je 413,32 USD und erhöhte damit ihren Direktbestand auf 403.904 Aktien. Sie hält außerdem weiterhin 36.648 Aktien über den betrieblichen Altersvorsorgeplan sowie 9.821 Aktien indirekt (7.300 als Treuhänderin des GST Trust und 2.521 im Besitz ihres Ehepartners). Es wurden keine Derivatgeschäfte gemeldet.

Der Kauf macht weniger als 0,005 % ihres direkten Besitzes aus und ist im Vergleich zu den 17 Millionen ausstehenden DDS-Aktien unerheblich, doch jeder Insiderkauf – insbesondere durch eine Führungskraft – kann als Vertrauenssignal gewertet werden. Es gab keine Verkäufe, Optionsausübungen oder Hinweise auf 10b5-1-Pläne, und die Einreichung bestätigt ihren fortlaufenden Status als leitende Angestellte und Direktorin.

Positive
  • Open-market insider purchase signals potential management confidence in DDS shares.
  • Executive retains a large equity stake (>400k shares), aligning interests with shareholders.
Negative
  • Purchase size is immaterial (~$7.9k), limiting informational value.
  • No additional context on strategic initiatives or financial performance accompanies the filing.

Insights

TL;DR: Tiny insider buy; sentimentally positive but financially immaterial.

The 19-share purchase (~$7.9k) is negligible versus Matheny’s >400k direct shares and DDS’s $7 bn market cap. However, the direction of trade is noteworthy: insiders at DDS have historically been net sellers, so any purchase—however small—may bolster market perception of management confidence amid volatile retail conditions. With no concurrent option grants or planned sales, the filing has symbolic but limited valuation impact.

TL;DR: Governance-neutral; reaffirms insider alignment through continued equity stake.

Matheny already holds a substantial 2.4% insider stake; the incremental purchase aligns incentives but does not materially alter ownership structure. Absence of 10b5-1 designation suggests discretionary buying, which markets often view more favorably. No red flags arise, and the filing maintains transparency requirements.

Dillard’s, Inc. (DDS) ha presentato il modulo Form 4 in data 02/07/2025, rivelando un modesto acquisto sul mercato aperto da parte dell'insider di lunga data Drue Matheny, Vicepresidente Esecutivo e Direttore. Il 30/06/2025 Matheny ha acquisito 19 azioni ordinarie di Classe A al prezzo di $413,32 ciascuna, portando la sua partecipazione diretta a 403.904 azioni. Continua inoltre a detenere 36.648 azioni tramite il piano pensionistico aziendale e 9.821 azioni indirettamente (7.300 come fiduciario del GST Trust e 2.521 detenute dal coniuge). Non sono state segnalate transazioni su strumenti derivati.

L'acquisto rappresenta meno dello 0,005% della sua proprietà diretta ed è irrilevante rispetto alle 17 milioni di azioni in circolazione di DDS, tuttavia qualsiasi acquisto da parte di un insider—soprattutto da un dirigente senior—può essere interpretato come un segnale di fiducia. Non sono state effettuate vendite, esercizi di opzioni o indicazioni di piani 10b5-1, e il documento conferma il suo status continuativo sia come dirigente che come direttore.

Dillard’s, Inc. (DDS) presentó el formulario Form 4 con fecha 02/07/2025, revelando una modesta compra en el mercado abierto por parte de la veterana insider Drue Matheny, Vicepresidenta Ejecutiva y Directora. El 30/06/2025 Matheny adquirió 19 acciones ordinarias Clase A a $413.32 cada una, aumentando su participación directa a 403,904 acciones. También mantiene 36,648 acciones a través del plan de jubilación de la empresa y 9,821 acciones indirectamente (7,300 como fideicomisaria del GST Trust y 2,521 en posesión de su cónyuge). No se reportaron transacciones de derivados.

La compra representa menos del 0.005% de su propiedad directa y es insignificante en comparación con las 17 millones de acciones en circulación de DDS, sin embargo, cualquier compra por parte de un insider—especialmente un ejecutivo senior—puede interpretarse como una señal de confianza. No hubo ventas, ejercicios de opciones ni indicios de planes 10b5-1, y el informe confirma su estatus continuo como oficial y directora.

Dillard’s, Inc. (DDS)는 2025년 7월 2일자 Form 4 제출서에서 오랜 내부자이자 부사장 겸 이사인 Drue Matheny의 소규모 공개 시장 매수를 공개했습니다. 2025년 6월 30일 Matheny는 주당 $413.32에 클래스 A 보통주 19주를 매수하여 직접 보유 주식을 403,904주로 늘렸습니다. 또한 회사 퇴직연금 계획을 통해 36,648주를 보유하고 있으며, 간접적으로 9,821주 (GST 신탁의 수탁자로서 7,300주, 배우자가 보유한 2,521주)를 보유 중입니다. 파생상품 거래는 보고되지 않았습니다.

이번 매수는 그녀의 직접 소유 지분의 0.005% 미만으로 DDS의 1,700만 주 유통 주식에 비해 미미하지만, 특히 고위 임원의 내부자 매수는 신뢰 신호로 해석될 수 있습니다. 매도, 옵션 행사, 10b5-1 계획 관련 사항은 없었으며, 제출서류는 그녀가 계속해서 임원 및 이사임을 확인합니다.

Dillard’s, Inc. (DDS) a déposé le formulaire Form 4 daté du 02/07/2025, révélant un achat modeste sur le marché libre par Drue Matheny, une initiée de longue date, Vice-Présidente Exécutive et Directrice. Le 30/06/2025, Matheny a acquis 19 actions ordinaires de Classe A à 413,32 $ chacune, portant sa détention directe à 403 904 actions. Elle détient également 36 648 actions via le plan de retraite de l'entreprise et 9 821 actions indirectement (7 300 en tant que fiduciaire du GST Trust et 2 521 détenues par son conjoint). Aucune transaction sur dérivés n'a été rapportée.

L'achat représente moins de 0,005 % de sa propriété directe et est insignifiant par rapport aux 17 millions d'actions en circulation de DDS, mais tout achat par un initié—particulièrement un cadre supérieur—peut être interprété comme un signe de confiance. Il n'y a eu aucune vente, exercice d'options ou indication de plan 10b5-1, et le dépôt confirme son statut continu en tant que dirigeante et directrice.

Dillard’s, Inc. (DDS) hat am 02.07.2025 eine Form 4-Einreichung vorgenommen, die einen moderaten Kauf am offenen Markt durch die langjährige Insiderin Drue Matheny, Executive Vice President und Direktorin, offenlegt. Am 30.06.2025 erwarb Matheny 19 Class A Stammaktien zu je 413,32 USD und erhöhte damit ihren Direktbestand auf 403.904 Aktien. Sie hält außerdem weiterhin 36.648 Aktien über den betrieblichen Altersvorsorgeplan sowie 9.821 Aktien indirekt (7.300 als Treuhänderin des GST Trust und 2.521 im Besitz ihres Ehepartners). Es wurden keine Derivatgeschäfte gemeldet.

Der Kauf macht weniger als 0,005 % ihres direkten Besitzes aus und ist im Vergleich zu den 17 Millionen ausstehenden DDS-Aktien unerheblich, doch jeder Insiderkauf – insbesondere durch eine Führungskraft – kann als Vertrauenssignal gewertet werden. Es gab keine Verkäufe, Optionsausübungen oder Hinweise auf 10b5-1-Pläne, und die Einreichung bestätigt ihren fortlaufenden Status als leitende Angestellte und Direktorin.

0001818844false00018188442025-06-272025-06-27
UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON, D.C. 20549FORM 8-KCURRENT REPORTPURSUANT TO SECTION 13 OR 15(d) OF THESECURITIES EXCHANGE ACT OF 1934Date of Report (Date of earliest event reported):  June 27, 2025DOGWOOD THERAPEUTICS, INC.(Exact Name of Registrant as Specified in Charter)
Delaware
001-39811
85-4314201
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)
44 Milton AvenueAlpharetta, GA30009
(Address of principal executive offices)(Zip Code)
Registrant’s telephone number, including area code:  (866) 620-8655(Former name or former address, if changed since last report): N/ASecurities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, par value $0.0001DWTXNasdaq Capital Market
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).Emerging growth company       If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.       

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On June 27, 2025, the Board of Directors of Dogwood Therapeutics, Inc. (the “Company”), approved a base salary increase for Angela Walsh, Chief Financial Officer of the Company, to $321,903 per year from $279,916, per year, as a result of a review of base salary levels for similar positions among peer companies. The salary increase for Ms. Walsh became effective on July 1, 2025.
2
SIGNATURESPursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 DOGWOOD THERAPEUTICS, INC.
   
 By:/s/ Angela Walsh
 Name:Angela Walsh
Title:Chief Financial Officer, Corporate Secretary and Treasurer
July 2, 2025
3

FAQ

How many Dillard’s (DDS) shares did Drue Matheny buy?

19 Class A shares purchased on 06/30/2025 at $413.32 each.

What is Matheny’s total direct ownership after this transaction?

She now directly owns 403,904 DDS shares.

Were any shares sold or derivatives exercised in this Form 4?

No. The filing reports only an acquisition; no sales or option exercises occurred.

Does the filing indicate a 10b5-1 trading plan?

No. The transaction is not marked as pursuant to Rule 10b5-1(c).

How many DDS shares does Matheny hold indirectly?

She controls 9,821 indirect shares: 7,300 via GST Trust and 2,521 through her spouse.
Virios Therapeutics, Inc.

NASDAQ:VIRI

VIRI Rankings

VIRI Latest News

VIRI Latest SEC Filings

VIRI Stock Data

4.30M
27.76M
1.69%
Biotechnology
Pharmaceutical Preparations
Link
United States
ALPHARETTA